AstraZeneca to Invest US$2 Billion to Expand Biologics and Clinical Manufacturing in Maryland
Introduction:
AstraZeneca has announced plans to invest US$2 billion in expanding its biologics and clinical manufacturing facilities in Maryland, USA.
Features:
The expanded facilities will increase the capacity to make medicines and materials needed for clinical trials.
They will use modern technologies like automation, AI, and data tools to make production more efficient and reliable.
Medicines produced will cover areas such as cancer, rare diseases, immune system conditions, and respiratory illnesses.
The Frederick site expansion will allow medicines for rare diseases to be made locally for the first time.
These projects are part of a larger plan in the US to strengthen medicine supply and support future developments.
Construction will follow environmentally responsible practices to save energy and reduce impact on the environment.
The facilities are expected to be ready by 2029 and will help in producing and supplying medicines for clinical use.
Specifications:
| Name: | AstraZeneca |
| Type: | New Construction |
| Budget: | US$2 billion |
| Year: | 2029 |
